Recent studies have demonstrated aberrant expression of cyclin B1 in several malignant cancers, including breast cancer [15], esophageal squamous cell carcinoma [16], non-small cell carcinoma [17], gastric cancer, and hepatocellular carcinoma [18,19]. This evidence concerns the gene CCNB1 and hepatocellular carcinoma.